Valbiotis SAS

Valbiotis SA is a company engaged in the research and development of dietary supplements aimed at preventing metabolic and cardiovascular diseases, operating in France and Asia. Its product portfolio includes supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. The company is developing TOTUM-63 for reducing fasting blood glucose and treating type 2 diabetes, TOTUM-854 in Phase II/III clinical trials for reducing systolic blood pressure, and TOTUM-448 for reducing hepatic steatosis. Additionally, Valbiotis offers an e-commerce delivery service in Belgium and Luxembourg. Incorporated in 2014, the company is based in Périgny, France.